Law360, New York (September 28, 2009) -- Direct purchaser plaintiffs in an antitrust class action alleging Biovail Corp. and GlaxoSmithKline PLC conspired to stifle the market for a generic version of antidepressant Wellbutrin XL have asked defendants to turn over market projections depicting how the generic would affect sales and prices for the branded bupropion.
The direct purchaser plaintiffs filed a motion Monday in the U.S. District Court for the Eastern District of Pennsylvania to compel discovery of documents relating to Biovail's and GSK’s market...
